Loading...
Market
Significant gene editing research milestone achieved by Regeneron and Mammoth in the first year
5
Resolution / Starting Odds
Discovery of a new CRISPR enzyme • 33%
Successful editing of a complex genetic condition in vitro • 33%
Patenting a novel delivery mechanism • 34%
Scientific journals or official press releases from either company
Story
Regeneron Invests $100M in Mammoth for CRISPR-Based Gene Editing Therapies
Apr 25, 2024, 11:30 AM
Regeneron Pharmaceuticals has announced a significant expansion into gene editing by partnering with Mammoth Biosciences. The collaboration aims to research, develop, and commercialize CRISPR-based gene editing therapies for various diseases, targeting multiple tissues and cell types. Regeneron will make a substantial financial commitment, including a $5 million upfront payment and a $95 million equity investment in the CRISPR startup, totaling $100 million. This move is part of Regeneron's broader strategy to deepen its capabilities in genetic medicines, including a recent acquisition in cell therapy and ongoing partnerships focused on developing treatments for rare diseases like transthyretin amyloidosis. Mammoth, which previously developed CRISPR technology for COVID-19 diagnostics, has shifted focus to smaller DNA-cutting enzymes that could be more easily delivered into tissues across the body.
View original story
Similar markets
Yes, for one therapy • 40%
Yes, for more than one therapy • 20%
No • 40%
Transthyretin Amyloidosis • 25%
Sickle Cell Disease • 25%
Cystic Fibrosis • 25%
Muscular Dystrophy • 25%
Cancer • 25%
Alzheimer's Disease • 25%
Cystic Fibrosis • 25%
Sickle Cell Disease • 25%
Approval • 33%
Request for additional data • 33%
Rejection • 33%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
$0-100 million • 25%
$101-500 million • 25%
$501 million - $1 billion • 25%
Over $1 billion • 25%
Regeneron • 50%
Mammoth Biosciences • 50%